• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Adlarity: A Second Cholinesterase Inhibitor Patch Is Approved

Adlarity: A Second Cholinesterase Inhibitor Patch Is Approved

January 1, 2022
From The Carlat Geriatric Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

On March 14, 2022, Adlarity (donepezil hydrochloride) received FDA approval for the treatment of patients with mild, moderate, or severe Alzheimer’s dementia. Adlarity is as effective as other cholinesterase inhibitors. It delivers donepezil through a once-weekly transdermal patch (versus the daily rivastigmine [Exelon] patch). Advantages include its ability to treat swallowing-compromised patients, fewer GI side effects, and convenience for caregivers. The Adlarity patch is applied to a patient’s back, upper buttock, or outer thigh once a week and is available in doses that deliver 5 mg/day or 10 mg/day of donepezil over seven days. 


Adlarity is expected to be available in fall 2022. While its cost has not yet been announced, we expect it to be much higher than its generic competitors, including the rivastigmine daily patch. Another disadvantage is that doses >10 mg/day have not been evaluated. For now, patients are recommended to wear only one patch at a time. 


—Stephanie Collier, MD, MPH, and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

    www.thecarlatreport.com
    Issue Date: January 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Introducing The Carlat Geriatric Psychiatry Report
    Welcoming Our New Editor-in-Chief
    CME Post-Test - Dementia, CGPR, January/February/March 2022
    How to Interview the Older Patient
    Aducanumab: What the FDA Approval Means for Clinicians
    How to Distinguish the Dementias
    Treating Dementia: An Approach From the United Kingdom
    Adlarity: A Second Cholinesterase Inhibitor Patch Is Approved
    DOWNLOAD NOW
    Featured Book
    • MFB7e_cover_sm.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • shutterstock_495683782.jpg
      General Psychiatry

      The Other Freud 1

      Sigmund Freud’s theories are challenged by his granddaughter, Sophie Freud.



      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.